非霍奇金淋巴瘤282例临床分析

Shu-ping Chen, Deng-shu Wu, Xie-lan Zhao
{"title":"非霍奇金淋巴瘤282例临床分析","authors":"Shu-ping Chen,&nbsp;Deng-shu Wu,&nbsp;Xie-lan Zhao","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL).</p><p><strong>Methods: </strong>Two hundred eighty two patients with NHL were retrospectively reviewed.</p><p><strong>Results: </strong>The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05).</p><p><strong>Conclusion: </strong>Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.</p>","PeriodicalId":13115,"journal":{"name":"Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University","volume":"28 3","pages":"237-9"},"PeriodicalIF":0.0000,"publicationDate":"2003-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].\",\"authors\":\"Shu-ping Chen,&nbsp;Deng-shu Wu,&nbsp;Xie-lan Zhao\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL).</p><p><strong>Methods: </strong>Two hundred eighty two patients with NHL were retrospectively reviewed.</p><p><strong>Results: </strong>The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05).</p><p><strong>Conclusion: </strong>Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.</p>\",\"PeriodicalId\":13115,\"journal\":{\"name\":\"Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University\",\"volume\":\"28 3\",\"pages\":\"237-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:分析非霍奇金淋巴瘤(NHL)的分型、分期及预后。方法:对282例非霍奇金淋巴瘤患者进行回顾性分析。结果:b细胞NHL的完全缓解率和5年生存率均高于t细胞NHL(P < 0.05)。低、中、重度NHL的CR率和5年生存率差异有统计学意义(P < 0.05)。多柔比星、环磷酰胺、长春新碱、强的松方案(CHOP)患者的CR率和5年生存率高于环磷酰胺、长春新碱、强的松、etoposide方案(COP + VP16)患者(P < 0.05)。结论:合理的分类和分期对非霍奇金淋巴瘤的预后起着重要作用。以chop为基础的治疗方案可作为首选和标准的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].

Objective: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL).

Methods: Two hundred eighty two patients with NHL were retrospectively reviewed.

Results: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05).

Conclusion: Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信